These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 24261027)

  • 1. The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
    Stragier E; Van Assche G
    Acta Gastroenterol Belg; 2013 Sep; 76(3):322-8. PubMed ID: 24261027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
    Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease.
    Caccaro R; D'Incá R; Sturniolo GC
    Expert Rev Clin Immunol; 2010 Jul; 6(4):551-8. PubMed ID: 20594128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H
    Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fecal lactoferrin in identifying and management of inflammatory bowel disease].
    Pac-Kozuchowska E; Krawiec P; Mroczkowska-Juchkiewicz A
    Pol Merkur Lekarski; 2014 Jul; 37(217):61-4. PubMed ID: 25154203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.
    Langhorst J; Boone J
    Drugs Today (Barc); 2012 Feb; 48(2):149-61. PubMed ID: 22384454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fecal Calprotectin in Inflammatory Bowel Disease].
    Lee J
    Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases].
    Iwańczak B; Iwańczak F
    Pol Merkur Lekarski; 2015 Dec; 39(234):389-92. PubMed ID: 26802694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.
    D'Incà R; Dal Pont E; Di Leo V; Ferronato A; Fries W; Vettorato MG; Martines D; Sturniolo GC
    Int J Colorectal Dis; 2007 Apr; 22(4):429-37. PubMed ID: 16838143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.